Lacosamide

Formulation

The table below describes the formulation of lacosamide and the controls morphine sulfate and gabapentin for the following in vivo experiments.

Experiment(s) Compound Dose(s) mg/kg Correction factor Dose volume mL/kg Route Vehicle Suspension / Solution
Pharmacokinetics Lacosamide 3, 30 1.00 5 PO PBS Solution
Irwin, Rotarod Lacosamide 3, 10, 30, 100 1.00 5 PO PBS Solution
Plantar incision, Lacosamide 1, 3, 10, 30 1.00 5 PO PBS Solution
L5/L6 SNL
Plantar incision, Morphine 6 1.33 1 SC Saline Solution
L5/L6 SNL
(Acetone)
L5/L6 SNL Gabapentin 60 1.00 1 PO Saline Solution
(von Frey)

L5/L6 SNL = L5/L6 spinal nerve ligation; PO = per os; SC = subcutaneous; PBS = phosphate-buffered saline pH 7.5


Results

Expand and Collapse accordion content

Method: Protein Binding
A table shows the results of rapid equilibrium dialysis to assess protein binding and percent recovery of lacosamide. In rat plasma, lacosamide was 8.9% bound to protein and 91.1% unbound and had a recovery of 116.7%. In rat brain homogenate, lacosamide was 10.8% bound to protein and 89.2% unbound and had a recovery of 106.8%. Acebutolol, quinidine, and warfarin were included in the study as controls and returned values consistent with literature values.

Method: Rat Rotarod Animals were balanced across treatment groups based on body weight. Animals that achieved a latency of 40 seconds during the baseline trial were included in the study. Experimenters assessing behavior were masked to treatment. Group size was determined using power analysis.
Two graphs show the latency for male or female rats to fall off a rotarod apparatus. Responses are shown at the following time points: baseline (before treatment) and at 1, 2, and 4 hours after treatment with vehicle (PBS, delivered PO) or lacosamide (3, 10, 30, or 100 mg/kg, delivered PO). There were 10 rats per group. No significant effects were found in a two-way repeated measures ANOVA for either sex. Data were analyzed using GraphPad Prism version 10.1.2.


This work was conducted by PsychoGenics Inc. (Paramus, NJ) in collaboration with PSPP, NINDS, NIH under contract # 75N95019D00026. Prescribing information for clinically used controls can be found at labels.fda.gov. Information for icons representing experimental design details can be found through the NINDS Office of Research Quality https://go.nih.gov/Yw2tHGI.